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Background: The reporting of serious adverse events (SAEs) in clinical trials is crucial to assess the balance between
benefits and risks. For trials with serious adverse events posted at ClinicalTrials.gov, we assessed the consistency
between SAEs posted at ClinicalTrials.gov and those published in corresponding journal articles.
Methods: All records from ClinicalTrials.gov up to February 2014 were automatically exported in XML format. Among
these, we identified all phase III or IV randomized controlled trials with at least one SAE posted. For a random sample
of 300 of these trials, we searched for corresponding publications using MEDLINE via PubMed and extracted safety
results from the articles.
Results: Among the sample of 300 trials with SAEs posted at ClinicalTrials.gov, 78 (26 %) did not have a corresponding
publication, and 20 (7 %) had a publication that did not match the ClinicalTrials.gov record. For the 202 remaining
trials, 26 published articles (13 %) did not mention SAEs, 4 (2 %) reported no SAEs, and 33 (16 %) did not report the
total number of SAEs per treatment group. Among the remaining 139 trials, for 44 (32 %), the number of SAEs per
group published did not match those posted at ClinicalTrials.gov. For 31 trials, the number of SAEs was greater at
ClinicalTrials.gov than in the published article, with a difference ≥30 % for at least one group for 21. Only 33 trials
(11 %) had a publication reporting matching numbers of SAE and describing the type of SAE.
Conclusions: Many trials with SAEs posted at ClinicalTrials.gov are not yet published, omit the reporting of these
SAEs in corresponding publications, or report a discrepant number of SAEs as compared with ClinicalTrials.gov.
These results underline the need to consult ClinicalTrials.gov for more information on serious harms.
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Randomized controlled trials (RCTs) are considered the
gold standard for assessing the effects of health care in-
terventions and form the basis for treatment decision-
making. Thus, all results from clinical trials should be
transparent and accessible to all [1–3]. Results should
report on efficacy and also on safety to provide an estima-
tion of the balance of benefits and risks [4, 5]. In particular,
serious adverse events (SAEs), defined as adverse events
that result in death, require inpatient hospitalization or the
prolongation of hospitalization, are life-threatening, or* Correspondence: agnes.dechartres@aphp.fr
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a congenital anomaly or birth defect [6], should always be
completely reported [7]. However, inadequate and underre-
porting of trial results, especially safety results, is common
[4, 5, 8, 9], which leads to biased evidence that can have
serious consequences for patients. A notable example is
the obscured reporting of cardiovascular risk with rofe-
coxib in the VIGOR study, in which naproxen, the con-
trol treatment, was presented as having a protective
effect [10–12].
To increase transparency, the 2007 US Food and Drug
Administration Amendments Act (FDAAA 801) required
that, after September 2008, results from clinical trials con-
ducted in the United States be made publicly available at
ClinicalTrials.gov within 1 year of the completion of theis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ing of adverse events was also mandatory [13]. All SAEs
as well as other non-SAEs above a specified frequency
threshold must be reported per group in addition to the
total number of patients at risk. In a recent study focusing
on reporting, we found that trial results, especially SAEs,
were more completely reported at ClinicalTrials.gov than
in corresponding published articles [16].
In this study, we examined the consistency between
SAEs posted at ClinicalTrials.gov and those published in
journals. We identified a random sample of trials with
SAEs posted at ClinicalTrials.gov to assess whether these
safety results were published and to compare the timing
of availability of SAEs between ClinicalTrials.gov and
publications as well as the number and type of SAEs
posted at ClinicalTrials.gov and those published in cor-
responding journal articles.Methods
Search for trials with SAEs posted at ClinicalTrials.gov
On February 2, 2014, we exported all records from Clin-
icalTrials.gov and, using R 3.1.1 [17] with the XML
package, we identified all completed phase III or IV
RCTs with at least one SAE posted at ClinicalTrials.gov.
We excluded trials with only one group, trials with ≥4
groups, and phase I, I/II, II, and II/III trials. Of all eli-
gible trials (n = 1580), we selected a random conveni-
ence sample of 300 trials to search for corresponding
publications in journals.Search for corresponding publications in journals
In June 2014, one of the authors (ET) searched for cor-
responding publications in journals using the link to pub-
lications provided at ClinicalTrials.gov whenever possible.
Also, MEDLINE was systematically searched via PubMed
by using the ClinicalTrials.gov identification number
(NCT number). If no publication was identified, MED-
LINE was searched again by using keywords for drug
names and condition studied. The articles identified by
the search had to match the corresponding trial in
terms of the information registered at ClinicalTrials.gov
(same objective, sample size, location, responsible party,
trial phase, and funding sponsor). If there were several
publications for a trial, all publications that matched the
time-frame indicated at ClinicalTrials.gov were selected.
Trials for which the published article reported a different
time-frame or number of groups were excluded.
A second reviewer (CR) checked the matching between
ClinicalTrials.gov and the corresponding published arti-
cles for all trials. All disagreements were resolved by dis-
cussion between the two reviewers with the help of a third
reviewer (AD) if needed.Data extraction
For the random sample of 300 trials with SAEs posted at
ClinicalTrials.gov, we extracted the following character-
istics from the records exported from ClinicalTrials.gov
by using R 3.1.1 [17]:
1) General characteristics of the trial: lead sponsor,
condition, and countries where the trial was conducted;
primary completion date (defined as the date of the final
collection of data for the primary outcome) and the
date when results were first posted. This date was
extracted from the archive record and differs from the
date on which results were first received, which is
available under Study Results at ClinicalTrials.gov. The
difference between these two dates relates to
ClinicalTrials.gov production and the vetting of the
results by the US National Institutes of Health.
2) Design of the trial: phase III or IV trial and parallel
or cross-over trial.
3) Interventions: details concerning the interventions
for the experimental and control groups.
4) SAEs: total number of SAEs, number of SAEs per
group, types of SAEs, number of SAEs per type per
group, and number of participants at risk per group.
We recorded the date when SAEs were first posted
from the archive record.
For all trials with corresponding publications, the fol-
lowing information was collected from published arti-
cles, including online supplements:
1) General characteristics of the publication: journal of
publication, first author, date of online publication,
type of journal (general medical, specialty), and
whether ClinicalTrials.gov NCT number was
reported in the published article.
2) SAEs: whether SAEs were reported and whether
they were reported by number per group. If the total
number of SAEs per group was not reported, we
noted whether the number of the most common
SAEs (those observed above a certain frequency or
threshold rate), number of SAEs related to treatment,
or toxicity-graded events were reported instead. We
also extracted the types of SAEs reported and noted
whether the number per type and per group was
reported. Again, if all types were not reported, we
noted whether the types reported were common
event types, those observed above a certain frequency
or threshold rate, those related to treatment, or
toxicity-graded events. We also collected the number
of participants at risk for each group.
If several publications were identified for the same
trial, we extracted safety results from all corresponding
Fig. 1 Flow of the selection of relevant trials
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ClinicalTrials.gov. For trials with multiple phases (e.g.
lead-in or induction, double-blind randomized treatment,
and follow-up or extension) reported at both Clinical-
Trials.gov and in published articles, we extracted SAE data
only for the double-blind randomized treatment period.
For published articles reporting pooled results from mul-
tiple trials, we considered the data to be missing if we
were unable to extract SAE data that corresponded to the
specific trial.
All data were extracted from the published article in-
dependently by two reviewers (ET, CR), independently of
data collected from ClinicalTrials.gov. One of the reviewers
(CR) was blinded to the hypothesis. All disagreements
were resolved by discussion to reach a consensus, in-
cluding intervention by a third reviewer (AD) in case of
discrepancies.
Statistical analysis
Descriptive data are reported with numbers (percentages)
and median (quartile 1–3 [Q1–3]). We compared time be-
tween primary completion date as reported at Clinical-
Trials.gov and date of the SAEs first publicly posted at
ClinicalTrials.gov or the date of the first online publication
in journals reporting the number of SAEs per group by
the Kaplan–Meier method. Trials for which the number
of SAEs per group were not reported in a published article
on June 2014 were censored at this date for the estimation
of time between the primary completion date and online
publication of SAEs. For trials with both results posted
and published, we compared the number of SAEs reported
at ClinicalTrials.gov and in the published article. To sim-
plify, for three-group trials with two groups representing
different doses of the same treatment, we combined these
two groups. For trials comparing three different treat-
ments, we selected the main comparison according to
the ClinicalTrials.gov posting and without knowledge
of the results. Analyses involved the use of R 3.1.1 [17].
Results
Figure 1 describes the selection of trials. Briefly, from
the 159,679 studies recorded at ClinicalTrials.gov on
February 2, 2014, there were 1,580 phase III or IV ran-
domized drug trials with two or three groups having re-
sults posted. We selected a random sample of 300 trials
to search for corresponding publications. Among the
300 trials, 78 (26 %) had no corresponding published
article. From the remaining 222 trials with results both
posted and published, we excluded 20 trials for which
the time-frame and/or number of groups reported in the
article did not match those posted at ClinicalTrials.gov.
Table 1 describes the characteristics of the 300 randomly
selected trials and the 202 trials with corresponding
published articles.Time to availability of SAEs at ClinicalTrials.gov and in
published articles
The difference between the median time to the availability
of SAEs at ClinicalTrials.gov and in published articles was
50 months (95 % confidence interval [95 % CI]: 26–98
months) with the median time between primary comple-
tion of trials and SAEs publicly posted at ClinicalTrials.gov
of 22 months (Q1–3, 15–35) and median time between
primary completion date and availability of SAEs in pub-
lished articles of 72 months (Q1–3, 27–119; Fig. 2).
Reporting of the number of SAEs per treatment group
From the 202 final pairs of trials, the number of SAEs per
group was reported in the published article for 139 (69 %);
26 (13 %) published articles did not mention SAEs at all
and 4 (2 %) reported no SAEs. Of these 30 articles, for 12
trials, the number of SAEs posted at ClinicalTrials.gov
was >10 and for 6, >100. For 33 trials, the reporting of
SAEs was incomplete in the published article: 10 reports
(5 %) described only drug-related SAEs or SAEs of interest
and 9 (4 %) reported adverse events with grade ≥3 instead.
In 8 articles, the results were pooled from several trials
and we were not able to extract the number of SAEs for
each individual trial. Three published articles (1 %) did
not report the number of SAEs per group, and 3 (1 %) re-
ported only SAEs for the experimental group (Fig. 3).
Among the 139 trials that reported SAEs per group in
the published article, for 44 (32 %), the number of SAEs
Table 1 Characteristics of the random sample of 300 phase III or IV trials with at least one serious adverse event (SAE) posted at
ClinicalTrials.gov for which publications were sought
Characteristic Sample of trials with at least one SAE posted at
ClinicalTrials.gov
Sample of trials with corresponding
published article
(n = 300) (n = 202)
Study phase
III 234 (78) 168 (83)
IV 66 (22) 34 (17)
Study design
Parallel groups 287 (95) 197 (97)
Cross-over 9 (3) 5 (3)
Factorial 2 (1) 0 (0)
Other 2 (1) 0 (0)
No. of intervention groups
Two 233 (78) 169 (88)
Three 60 (20) 33 (12)
Other 7 (2) 0 (0)
Primary funding source
Industry 264 (88) 178 (88)
US National Institutes of Health 8 (3) 7 (3)
US federal funding 1 (0) 1 (1)
Other 27 (9) 16 (8)
Medical condition
Endocrinology 41 (14) 32 (16)
Infectious diseases 38 (13) 22 (11)
Cardiology 31 (10) 18 (9)
Neurology 29 (10) 23 (11)
Oncology 29 (10) 23 (11)
Rheumatology 22 (7) 13 (7)
Pulmonary 20 (6) 15 (7)
Other 90 (30) 56 (28)
Study location
At least one site in the United States 205 (68) 140 (69)




ClinicalTrials.gov NCT reported in article
Yes 162 (80)
No 40 (20)
Data are no. (%)
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for 32 of these, the number of SAEs was different for both
groups and, for 12, only one group. For the 32 trials with
number of SAEs different for both groups, 22 (69 %) had
more SAEs reported at ClinicalTrials.gov than in the pub-
lished articles. For 15 of these trials (68 %), the differencebetween the number posted at ClinicalTrials.gov and
the published article was ≥30 % for at least one group.
For the 12 trials where number of SAEs was different
for one group only, 9 trials had more SAEs reported at
ClinicalTrials.gov than in the published article. For 6






























Fig. 2 Comparison of time from primary completion date to posting of serious adverse events (SAEs) per group at ClinicalTrials.gov and to the
reporting of SAEs per group in published articles
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was ≥30 %.
Reporting of details of SAEs
Of the 95 trials with number of SAEs matching that at
ClinicalTrials.gov, all types of SAEs that occurred were
reported for 33 (35 %) in the corresponding published
articles. In 34 published articles (36 %), the type of SAE
was not reported at all. Other publications reported the
types of SAEs for only drug-related SAEs (n = 12), the
most common SAEs (n = 10), the SAEs of interest (n = 5),
or SAEs leading to withdrawal (n = 1).
Overall, only 33 trials (11 %) out of the random sample
of 300 trials with SAEs posted at ClinicalTrials.gov had a
publication reporting matching SAE numbers and de-
scribing the type of SAE (Fig. 3). The characteristics of
these 33 trials are presented in Table 2. In brief, 88 % of
these trials were phase III trials, 82 % had a private fund-
ing source, 73 % had at least one site in the United
States, and 73 % were published in a specialty journal.
Discussion
Herein, we identified a random sample of trials with
SAEs posted at ClinicalTrials.gov to assess whether these
safety results were reported in published articles and, if
yes, whether there were discrepancies between the publi-
cation and the registry data. Our results highlight that
the reporting of SAEs in published articles remains a
major problem. For a sample of 300 trials with SAEsposted at ClinicalTrials.gov, among 202 with a matching
publication, 30 (15 %) did not mention SAEs or reported
no SAEs in the corresponding publications. The number
of SAEs per group was frequently not reported in the pub-
lished articles and when it was reported, discrepancies with
the numbers posted at ClinicalTrials.gov were common,
with frequently more SAEs reported at ClinicalTrials.gov
than in the published article.
Restricted space in articles is a frequently cited reason
for incomplete reporting of harms [4, 18]. However, the
assessment of the balance between benefits and risks
should be the core of trial reports. Failure to report SAEs
may lead to a biased safety profile and erroneous decision-
making, with major consequences for patients. Despite
the extension of the Consolidated Standards of Reporting
Trials (CONSORT) statement published in 2004, which
provides guidelines on reporting harms-related data [7],
reporting of safety data in published articles of clinical
trials continues to be suboptimal [5, 16, 19, 20], with
poor adherence to the statement [21–24]. According to
a recent study, only 63 % of published articles reported
the total number of SAEs by group [16].
In a previous article focusing on completeness of report-
ing, we found that SAEs were significantly more completely
reported at ClinicalTrials.gov than in the published ar-
ticles (99 % vs. 63 %, P <0.0001) [16]. This result was
particularly troubling, but one explanation could be that
SAEs were not reported in published articles because
there were none.
202 Trials with results published
33 trials (11%) with SAEs posted at ClinicalTrials.gov and adequately reporting SAEs 
in published articles
No corresponding publication n=98 
• No publication (n=78)
• Time frame or group not matching 
(n=20)
139 Trials reporting the number of SAEs per group in 
publications
No. of SAEs in publications not matching 
ClinicalTrials.gov n=44 
• More SAEs at ClinicalTrials.gov than in published 
articles for 31 trials (Difference  30% in 21 trials)
95 Trials with number of SAEs in publications 
matching  that at ClinicalTrials.gov
Type of SAEs not described in 
publications n=62 
• No description (n=34)
• Drug- related SAEs (n=12)
• Most common SAEs (n=10)
• SAEs of interest (n=5)
• Withdrawals only (n=1)
33 Trials with types of SAEs 
described in publications
300 Random sample of  trials with SAEs posted at ClinicalTrials.gov
No. of SAEs not fully reported in corresponding 
publications n=63 
• Not mentioned or no SAE (n=30)
• Specific SAE only (n=19)
• Pooled results (n=8)
• Not for each group (n=6)
Fig. 3 Reporting of serious adverse events (SAEs) in published articles for a random sample of 300 trials with SAEs posted at ClinicalTrials.gov
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or reporting no SAEs in the published article, despite
these being reported at ClinicalTrials.gov. Furthermore,
when SAEs were reported in published articles, discrep-
ancies with the number posted at ClinicalTrials.gov were
common, with frequently more SAEs reported at Clini-
calTrials.gov than in the published article. Although we
do not know which the ‘true’ results are, we believe that
these discrepancies clearly outline problems in the report-
ing of SAEs. Two studies comparing results posted at
ClinicalTrials.gov and in peer-reviewed publications also
showed discrepancies in the number of SAEs [18, 25, 26].
The originality of our approach was the identification
of trials for which we had knowledge of SAEs to assess
whether and how these safety results were reported in
published articles.
Our results have important implications. Our results
highlight that ClinicalTrials.gov provide more information
on serious harms, whereas these events are frequently
underreported in published articles. For systematic re-
viewers, they outline the interest of using ClinicalTrials.gov
to find safety results not yet published in journals and for
trials with both SAEs posted and published, to comparethe rate of SAEs. In case of discrepancies, we recommend
systematically contacting authors for clarification and
performing sensitivity analyses in case of non-response
to assess to what extent these discrepancies may affect
the meta-analysis result. For journals, they question the
peer-review process, in that the assessment of data re-
corded in registries including results and harms when
available should be part of the process to assess if there
are any discrepancies that could bias the results. In case
of discrepancies, investigators should be contacted for
clarification. They also raise questions about how report-
ing guidelines, especially the CONSORT harms, are im-
plemented by journals, with a need for more active
endorsement. Templates with mandatory reporting of
critical elements, such as that used at ClinicalTrials.gov
[14], could improve the reporting of safety results in
journals. For policymakers, our results advocate an ex-
tension to all countries of the mandatory posting of trial
results. Besides their use for limiting publication bias and
selective outcome reporting, public registries may help
improve transparency of results in clinical trials. Ac-
cordingly, in April 2014, the European Union voted to
adopt the Clinical Trials Regulation, which requires the
Table 2 Characteristics of the 33 trials with adequate reporting







Parallel groups 31 (94)
Cross-over 2 (6)





US National Institutes of Health 2 (6)












At least one site in the United States 24 (73)




ClinicalTrials.gov NCT reported in article
Yes 27 (82)
No 6 (18)
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and posting of trial summary results in the European
Clinical trials Database (EudraCT) within 1 year after
trial completion [27, 28]. Nevertheless, compliance to the
legal requirement in the United States is low [16, 29–33]
despite civil monetary penalties (up to $10,000 a day) and,
for federally funded studies, the withholding of grant
funds in cases of non-compliance [14]. Therefore, compli-
ance must be improved. A recent article showed that
sending emails to responsible parties of completed trials
that do not comply with the FDAAA legal requirement topost results significantly improved the posting rate at 6
months [34].
Limitations
We may not have identified all published articles be-
cause we searched only MEDLINE for publications. Fur-
ther, for trials without publications, the results could be
published at a future date because publication in jour-
nals may take time due to multiple submissions. Some
trials may have multiple publications with different results
reported. In this case, we did not include all reports result-
ing from the trial but only the reports that included
safety data and matched the time frame reported at
ClinicalTrials.gov. Finally, this study focused on trials asses-
sing pharmacological treatments, but non-pharmacological
treatments can also incur SAEs.
Conclusions
Our results reveal that many trials with SAEs posted
at ClinicalTrials.gov are not yet published, omit the
reporting of these SAE in corresponding publications,
or report a discrepant number of SAEs as compared
with ClinicalTrials.gov. Consulting safety results posted at
ClinicalTrials.gov, when available, is crucial for more in-
formation on serious harms.
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